Review of mechanism of interleukin regulatory network in inflammatory bowel disease

doi:10.3969/j.issn.1674-8115.2026.06.013

Abstract

Abstract:

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is a heterogeneous group of disorders characterized by chronic and recurrent gastrointestinal inflammation. The pathophysiological mechanisms of IBD are complex, involving numerous factors, including genetics, environmental exposure, dysbiosis of the gut microbiota, and abnormal immune responses, with the disruption of immune homeostasis being a central pathological component. Studies have shown that abnormal regulation of cytokine networks plays a key role in the onset and progression of IBD. Among these, interleukins (ILs), as a class of important signaling molecules, have attracted widespread attention in the pathogenesis and clinical treatment of IBD, and targeted therapies against ILs have demonstrated significant efficacy. This article systematically elucidates the association between ILs and IBD, provides an in-depth analysis of the mechanisms by which ILs function in the pathogenesis of IBD, and discusses the imbalance between pro-inflammatory ILs (such as IL-6, IL-17, and IL-23) and the anti-inflammatory IL-10, as well as the regulation of their corresponding signaling pathways. It also summarizes IL-targeted therapeutic strategies, including the clinical validation of biologics and novel therapies, with the aim of providing new tactics for the clinical management of IBD.

Key words: interleukin, inflammatory bowel disease, immune regulation, targeted therapy

CLC Number:

R574.62

Li Mengru, Wang Haiqiang. Review of mechanism of interleukin regulatory network in inflammatory bowel disease[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026, 46(6): 801-809.

Figures/Tables 2

TrendMD

References 68

[1]	Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. Pathophysiology of inflammatory bowel disease: innate immune system[J]. Int J Mol Sci, 2023, 24(2): 1526.
[2]	Hracs L, Windsor J W, Gorospe J, et al. Global evolution of inflammatory bowel disease across epidemiologic stages[J]. Nature, 2025, 642(8067): 458-466.
[3]	Prioritizing inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2025, 22(6): 361.
[4]	Nakajima M, Iwao Y, Okabayashi K, et al. Pathological characteristics of inflammatory bowel diseases[J]. J Med Ultrason, 2025, 52(2): 187-196.
[5]	Lu Q, Yang M F, Liang Y J, et al. Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics[J]. J Inflamm Res, 2022, 15: 1825-1844.
[6]	Padoan A, Musso G, Contran N, et al. Inflammation, autoinflammation and autoimmunity in inflammatory bowel diseases[J]. Curr Issues Mol Biol, 2023, 45(7): 5534-5557.
[7]	Vebr M, Pomahačová R, Sýkora J, et al. A narrative review of cytokine networks: pathophysiological and therapeutic implications for inflammatory bowel disease pathogenesis[J]. Biomedicines, 2023, 11(12): 3229.
[8]	Uchiyama K, Takagi T, Mizushima K, et al. Mucosal interleukin-8 expression as a predictor of subsequent relapse in ulcerative colitis patients with Mayo endoscopic subscore 0[J]. J Gastroenterol Hepatol, 2022, 37(6): 1034-1042.
[9]	Wang C Y, Lv G Q, Chen E B, et al. Cross-trait cross-genome cross-organ analysis of gastrointestinal disorders and depression[J]. Dig Dis Sci, 2025, 70(9): 3021-3033.
[10]	Li X C, Zhao C B. Interleukin-6 in neuroimmunological disorders: pathophysiology and therapeutic advances with satralizumab[J]. Autoimmun Rev, 2025, 24(7): 103826.
[11]	Song M, Wang Y L, Annex B H, et al. Experiment-based computational model predicts that IL-6 trans-signaling plays a dominant role in IL-6 mediated signaling in endothelial cells[J]. bioRxiv, 2023: 2023.02.03.526721.
[12]	Rose-John S, Jenkins B J, Garbers C, et al. Targeting IL-6 trans-signalling: past, present and future prospects[J]. Nat Rev Immunol, 2023, 23(10): 666-681.
[13]	Li X T, Wu X Y, Chen X Q, et al. Selective blockade of interleukin 6 trans-signaling depresses atrial fibrillation[J]. Heart Rhythm, 2023, 20(12): 1759-1770.
[14]	Forcina L, Franceschi C, Musarò A. The hormetic and hermetic role of IL-6[J]. Ageing Res Rev, 2022, 80: 101697.
[15]	Agca S, Kir S. The role of interleukin-6 family cytokines in cancer cachexia[J]. FEBS J, 2024, 291(18): 4009-4023.
[16]	Ji T, Huang G H, Cao Y D, et al. Advances in interleukin-6 family cytokines and the role in respiratory diseases[J]. J Inflamm Res, 2025, 18: 3125-3141.
[17]	Naganuma M, Takeno M, Çelik A F, et al. Assessment of IL-6 pathway inhibition in gastrointestinal behçet's disease from immunological and clinical perspectives[J]. Biomedicines, 2025, 13(1): 247.
[18]	Alhendi A, Naser S A. The dual role of interleukin-6 in Crohn's disease pathophysiology[J]. Front Immunol, 2023, 14: 1295230.
[19]	Tie Y Z, Chen M H, Zhang S H. Insights into the molecular mechanisms and therapeutic implications of interleukin-6 for inflammatory bowel disease[J]. Chin Med J, 2023, 136(18): 2143-2146.
[20]	Zhang S H, Chen B L, Wang B M, et al. Effect of induction therapy with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial[J]. JAMA, 2023, 329(9): 725-734.
[21]	Koureta E, Karatzas P, Kanellopoulos P N, et al. The importance of growth differentiation factor 15 and interleukin 6 serum levels in inflammatory bowel diseases[J]. J Physiol Biochem, 2025, 81(1): 111-122.
[22]	Knyazev O, Kagramanova A V. P0578 The relationship between the concentration of D-dimer and interleukin-6 in patients with ulcerative colitis[J]. J Crohn's Colitis, 2025, 19(Supplement_1): i1155.
[23]	Samarani S, Dupont-Lucas C, Marcil V, et al. CpG methylation in TGFβ1 and IL-6 genes as surrogate biomarkers for diagnosis of IBD in children[J]. Inflamm Bowel Dis, 2020, 26(10): 1572-1578.
[24]	Narazaki M, Kishimoto T. Current status and prospects of IL-6-targeting therapy[J]. Expert Rev Clin Pharmacol, 2022, 15(5): 575-592.
[25]	Schreiber S, Aden K, Bernardes J P, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease[J]. Gastroenterology, 2021, 160(7): 2354-2366.e11.
[26]	Avci A B, Feist E, Burmester G R. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned [J]. BioDrugs, 2024, 38(1): 61-71.
[27]	Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update[J]. Ann Rheum Dis, 2023, 82(6): 773-787.
[28]	Yu Z, Li X L, Huang J Y, et al. The RNA-binding E3 ligase MKRN2 selectively disrupts Il6 translation to restrain inflammation[J]. Nat Immunol, 2025, 26(7): 1036-1047.
[29]	Guo S S, Geng W Y, Chen S, et al. Ginger alleviates DSS-induced ulcerative colitis severity by improving the diversity and function of gut microbiota[J]. Front Pharmacol, 2021, 12: 632569.
[30]	Huangfu L J, Li R Y, Huang Y M, et al. The IL-17 family in diseases: from bench to bedside[J]. Signal Transduct Target Ther, 2023, 8(1): 402.
[31]	Liu Y C, Ouyang Y, You W C, et al. Physiological roles of human interleukin-17 family[J]. Exp Dermatol, 2024, 33(1): e14964.
[32]	Deng G Z, Guo M D, Fan J H, et al. Interleukin-17 family in health and immune diseases: from origin to clinical implications[J]. Neural Regen Res, 2026, 21(5): 1809-1833.
[33]	Koh C H, Kim B S, Kang C Y, et al. IL-17 and IL-21: their immunobiology and therapeutic potentials[J]. Immune Netw, 2024, 24: e2.
[34]	Li J, Liu L, Zhao Q, et al. Role of interleukin-17 in pathogenesis of intestinal fibrosis in mice[J]. Dig Dis Sci, 2020, 65(7): 1971-1979.
[35]	Brabec T, Vobořil M, Schierová D, et al. IL-17-driven induction of Paneth cell antimicrobial functions protects the host from microbiota dysbiosis and inflammation in the ileum[J]. Mucosal Immunol, 2023, 16(4): 373-385.
[36]	Chong W P, Mattapallil M J, Raychaudhuri K, et al. The cytokine IL-17A limits Th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24[J]. Immunity, 2020, 53(2): 384-397.e5.
[37]	Goepfert A, Lehmann S, Blank J, et al. Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-independent signaling[J]. Immunity, 2020, 52(3): 499-512.e5.
[38]	Vangilbergen M, Stockman A, van de Velde A, et al. The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: a systematic review[J]. JAAD Int, 2024, 17: 71-79.
[39]	Deng Z Z, Wang S F, Wu C F, et al. IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis[J]. Front Pharmacol, 2023, 14: 1124628.
[40]	Munshi A R, Wang T, Takamori Y, et al. SELEX-discovered aptamer that inhibits cellular interleukin-17/interleukin-17 receptor interaction and antagonizes interleukin-17 signaling[J]. Biosci Biotechnol Biochem, 2024, 88(2): 147-153.
[41]	Mills K H G. IL-17 and IL-17-producing cells in protection versus pathology[J]. Nat Rev Immunol, 2023, 23(1): 38-54.
[42]	Gandhi G R, Mohana T, Athesh K, et al. Anti-inflammatory natural products modulate interleukins and their related signaling markers in inflammatory bowel disease: a systematic review[J]. J Pharm Anal, 2023, 13(12): 1408-1428.
[43]	Liang J, Dai W G, Liu C H, et al. Gingerenone a attenuates ulcerative colitis via targeting IL-17RA to inhibit inflammation and restore intestinal barrier function[J]. Adv Sci (Weinh), 2024, 11(28): e2400206.
[44]	Biskup L, Semeradt J, Rogowska J, et al. New interleukin-23 antagonists' use in Crohn's disease[J]. Pharmaceuticals (Basel), 2025, 18(4): 447.
[45]	Vuyyuru S K, Shackelton L M, Hanzel J, et al. Targeting IL-23 for IBD: rationale and progress to date[J]. Drugs, 2023, 83(10): 873-891.
[46]	Tian Z Z, Zhao Q R, Teng X. Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease[J]. Front Immunol, 2024, 15: 1393463.
[47]	Korta A, Kula J, Gomułka K. The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease[J]. Int J Mol Sci, 2023, 24(12): 10172.
[48]	Sewell G W, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention[J]. J Crohns Colitis, 2022, 16(Supplement_2): ii3-ii19.
[49]	Louis E. Use of interleukin-23 inhibitors for the treatment of inflammatory bowel disease[J]. Gastroenterol Hepatol (N Y), 2025, 21(3): 180-182.
[50]	Krueger J G, Eyerich K, Kuchroo V K, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy[J]. Front Immunol, 2024, 15: 1331217.
[51]	Jacobse J, Brown R E, Li J, et al. Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells[J]. Cell Rep, 2023, 42(2): 112128.
[52]	D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials[J]. Lancet, 2022, 399(10340): 2015-2030.
[53]	Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial[J]. Lancet, 2022, 399(10340): 2031-2046.
[54]	Ferrante M, D'Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study[J]. Lancet, 2024, 404(10470): 2423-2436.
[55]	Sands B E, Panaccione R, Danese S, et al. P0608 Safety of guselkumab in inflammatory bowel disease up to 1 year: integrated safety analysis of phase 2 and 3 studies in Crohn's disease and ulcerative colitis[J]. J Crohns Colitis, 2025, 19(Supplement_1): i1205-i1207.
[56]	Chang C C, Yang C H, Chuang C H, et al. A peptide derived from interleukin-10 exhibits potential anticancer activity and can facilitate cell targeting of gold nanoparticles loaded with anticancer therapeutics[J]. Commun Chem, 2023, 6(1): 278.
[57]	York A G, Skadow M H, Qu R H, et al. IL-10 constrains sphingolipid metabolism via fatty acid desaturation to limit inflammation[J]. bioRxiv, 2023: 2023.05.07.539780.
[58]	Carlini V, Noonan D M, Abdalalem E, et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions[J]. Front Immunol, 2023, 14: 1161067.
[59]	Saxton R A, Tsutsumi N, Su L L, et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10[J]. Science, 2021, 371(6535): eabc8433.
[60]	DiDonato M, Simpson C T, Vo T, et al. A novel interleukin-10 antibody graft to treat inflammatory bowel disease[J]. Structure, 2025, 33(3): 475-488.e7.
[61]	Chen X T, Zhang M M, Zhou F, et al. SIRT3 activator honokiol inhibits Th17 cell differentiation and alleviates colitis[J]. Inflamm Bowel Dis, 2023, 29(12): 1929-1940.
[62]	Pavel C, Diculescu M M, Ilie M, et al. Immunohistochemistry analysis in inflammatory bowel disease-should we bring to light interleukin-10 [J]. Biomedicines, 2025, 13(2): 406.
[63]	York A G, Skadow M H, Oh J, et al. IL-10 constrains sphingolipid metabolism to limit inflammation[J]. Nature, 2024, 627(8004): 628-635.
[64]	Eddie Ip W K E, Hoshi N, Shouval D S, et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages[J]. Science, 2017, 356(6337): 513-519.
[65]	Steen E H, Wang X Y, Balaji S, et al. The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis[J]. Adv Wound Care, 2020, 9(4): 184-198.
[66]	Carrasco A, Tristán E, Fernández-Bañares F, et al. Mucosal interleukin-10 depletion in steroid-refractory Crohn's disease patients[J]. Immun Inflamm Dis, 2022, 10(10): e710.
[67]	Li L L, Ma C X, Chen K X, et al. Integrated transcriptomic and proteomic profiling of colonic tissue in interleukin-10-deficient mice[J]. Sci Data, 2025, 12(1): 1109.
[68]	Wang Y F, Liu D D, Gao H L, et al. Treatment of IL-10RA deficiency of pediatric patients with very early onset inflammatory bowel disease by allogeneic haematopoietic stem cell transplantation[J]. Sci Rep, 2025, 15(1): 9606.